Totally agree, but I'd be lying if I said I wouldn't take a $5.4B valuation for K with a phase 1 trial completion right now, plus the $4B more later on down the line. That's pretty sweet and puts CTIX up in the $30+ pps range with growth into the $70 pps range with the additional future funds. That will still leaves B and the darkhorse P to further boost valuation. That sounds like a good scenario to my ears.